Sen. Murray Prods FDA To Clarify 510(k) Modification Policies In Superbug Bill
This article was originally published in The Gray Sheet
Following up on recommendations made in her January report on duodenoscope contamination, Senate HELP Ranking Member Patty Murray, D-Wash., introduced a bill pressing FDA to accelerate its work to clarify when 510(k)s are needed for device modifications and to solidify the agency's authority to deny submissions if the sponsor fails to provide validated reprocessing data.
You may also be interested in...
After years of controversy, US FDA finally succeeded in updating its 20-year-old guideline on when a new 510(k) is needed for device modifications. Split out as its own document is a guideline targeting the issue specifically for software modifications.
US FDA wants sponsors to complete risk-based assessments and thoroughly consider unintended outcomes of changes they make to already-cleared devices, says a new, highly anticipated draft guidance on 510(k) modifications. This is true whether alterations are made by manufacturers to improve safety or effectiveness, enhance labels, change technology or engineering, or to upgrade materials in a device.
The Healthcare Leadership Council – a coalition of health care CEOs – wants Congress to allow more waivers for accountable care organizations from the anti-kickback statute and the Stark law, which protects against physician self-referrals, and are also pushing the same slate of device regulatory reforms as in the House-approved 21st Century Cures bill.